Corbus Pharmaceuticals Announces Three Lenabasum Abstracts to be Presented at ACR Convergence 2020
21 oct. 2020 08h05 HE
|
Corbus Pharmaceuticals Holdings, Inc.
Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...